3347 Stock Overview
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥37.15 |
52 Week High | CN¥69.50 |
52 Week Low | CN¥22.10 |
Beta | 0.71 |
1 Month Change | 33.39% |
3 Month Change | 52.57% |
1 Year Change | -43.46% |
3 Year Change | -74.27% |
5 Year Change | n/a |
Change since IPO | -67.21% |
Recent News & Updates
Recent updates
Shareholder Returns
3347 | HK Life Sciences | HK Market | |
---|---|---|---|
7D | 8.3% | 3.7% | 2.4% |
1Y | -43.5% | -63.1% | -8.7% |
Return vs Industry: 3347 exceeded the Hong Kong Life Sciences industry which returned -64.9% over the past year.
Return vs Market: 3347 underperformed the Hong Kong Market which returned -7.9% over the past year.
Price Volatility
3347 volatility | |
---|---|
3347 Average Weekly Movement | 10.9% |
Life Sciences Industry Average Movement | 10.8% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 15.0% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 3347's share price has been volatile over the past 3 months.
Volatility Over Time: 3347's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 9,701 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
3347 fundamental statistics | |
---|---|
Market cap | HK$54.22b |
Earnings (TTM) | HK$1.83b |
Revenue (TTM) | HK$7.84b |
31.6x
P/E Ratio7.4x
P/S RatioIs 3347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3347 income statement (TTM) | |
---|---|
Revenue | CN¥7.24b |
Cost of Revenue | CN¥4.48b |
Gross Profit | CN¥2.76b |
Other Expenses | CN¥1.07b |
Earnings | CN¥1.69b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.96 |
Gross Margin | 38.10% |
Net Profit Margin | 23.36% |
Debt/Equity Ratio | 13.2% |
How did 3347 perform over the long term?
See historical performance and comparison